BRIEF published on 02/11/2026 at 22:35, 1 month 25 days ago Integrated BioPharma Announces Q4 2025 Financial Results Financial Results Revenue Decline Net Loss Operating Loss Customer Dependency
PRESS RELEASE published on 02/11/2026 at 22:30, 1 month 25 days ago Integrated BioPharma Reports Results for Its Quarter Ended December 31, 2025 Integrated BioPharma, Inc. reports financial results for Q4 2025, showing a $1.3M decrease in revenue and operating loss compared to Q4 2024. Key financial details provided Financial Results Revenue Decrease Operating Loss Integrated BioPharma Quarterly Performance
BRIEF published on 11/10/2025 at 21:55, 4 months 28 days ago Integrated BioPharma Reports Financial Results for Q3 2025 Financial Results Net Income Revenue Decline Operating Income Contract Manufacturing
PRESS RELEASE published on 11/10/2025 at 21:50, 4 months 28 days ago Integrated BioPharma Reports Results for Its Quarter Ended September 30, 2025 Integrated BioPharma, Inc. reports financial results for the quarter ended September 30, 2025, with $12.7 million revenue and insights on operating income and net income Financial Results Revenue Net Income Operating Income Integrated BioPharma
BRIEF published on 09/23/2025 at 21:45, 6 months 15 days ago Integrated BioPharma Reports Fiscal Year 2025 Results Financial Results Revenue Growth Net Income Operating Income Contract Manufacturing
PRESS RELEASE published on 09/23/2025 at 21:40, 6 months 15 days ago Integrated BioPharma Reports Results for its Quarter and Fiscal Year Ended June 30, 2025 Integrated BioPharma, Inc. reports 11.8% increase in revenue for Q2 2025. Operating income rises in Q2 & FY 2025. Net loss in Q2 but net income grows for FY 2025 Revenue Increase Net Income Net Loss Operating Income Integrated BioPharma
BRIEF published on 05/14/2025 at 21:35, 10 months 25 days ago Integrated BioPharma, Inc. Posts Financial Results for Q1 2025 Financial Results Revenue Growth Operating Income Q1 2025 Key Customers
PRESS RELEASE published on 05/14/2025 at 21:30, 10 months 25 days ago Integrated BioPharma Reports Results for its Quarter Ended March 31, 2025 Integrated BioPharma, Inc. reports a 6.1% revenue increase for Q1 2025 compared to Q1 2024. Company had operating income and net income growth. Key focus on core business and expanding customer base Financial Results Revenue Increase Net Income Operating Income Integrated BioPharma
BRIEF published on 02/13/2025 at 22:00, 1 year 1 month ago Integrated BioPharma Reports Quarterly Results with Increased Revenue Revenue Growth Q4 Results Operating Income Customer Base Expansion Integrated BioPharma
PRESS RELEASE published on 02/13/2025 at 21:55, 1 year 1 month ago Integrated BioPharma Reports Results for its Quarter Ended December 31, 2024 Integrated BioPharma, Inc. reports 9.6% increase in revenue to $12.6 million for quarter ended Dec 31, 2024. Operating income of $0.2 million. Detailed financial results provided Financial Results Revenue Increase Quarterly Report Operating Income Integrated BioPharma
Published on 04/09/2026 at 19:15, 1 hour 11 minutes ago Murchison Minerals Announces Adoption of Quarterly Reporting Exemption Under Coordinated Blanket Order 51-933
Published on 04/09/2026 at 16:00, 4 hours 26 minutes ago Banff Half Marathon Completes 2025 Emissions Assessment, Supporting Climate Action with Karbon-X
Published on 04/09/2026 at 14:40, 5 hours 46 minutes ago Silver X Delivers Production Growth During the First Quarter of 2026
Published on 04/09/2026 at 14:00, 6 hours 26 minutes ago Orogen Royalties Announces Mineral Reserve and Resource Update on Producing Ermitaño Royalty
Published on 04/09/2026 at 13:30, 6 hours 56 minutes ago Datametrex Receives $6M Purchase Order for Data Centre from Fortune 500 Conglomerate
Published on 04/09/2026 at 18:15, 2 hours 10 minutes ago REPLY: Launch of a share buyback program for a maximum number of 3,607,950 shares
Published on 04/09/2026 at 15:40, 4 hours 46 minutes ago Form 8.3 - The Vanguard Group, Inc.: LondonMetric Property plc
Published on 04/09/2026 at 18:35, 1 hour 51 minutes ago Availability of proxy documents for the Combined General Meeting of April 30, 2026
Published on 04/09/2026 at 15:57, 4 hours 28 minutes ago Filing of CNP Assurances SA 2025 universal registration document and 2025 Solvency and Financial Condition Reports
Published on 04/09/2026 at 07:00, 13 hours 26 minutes ago bioMérieux Unveils its BIOFIRE® SPOTFIRE® Molecular Testing Solution for the Pharmaceutical Industry, Redefining Rapid Mycoplasma Testing
Published on 04/08/2026 at 18:02, 1 day 2 hours ago Publication of the 2025 Universal Registration Document
